2.11
-0.05(-2.31%)
Currency In USD
| Previous Close | 2.16 |
| Open | 2.14 |
| Day High | 2.2 |
| Day Low | 2.08 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.52 |
| Volume | 72,708 |
| Average Volume | 200,816 |
| Market Cap | 55.03M |
| PE | 5.7 |
| EPS | 0.37 |
| Moving Average 50 Days | 3.19 |
| Moving Average 200 Days | 3.37 |
| Change | -0.05 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $21.14 as of June 30, 2025 at a share price of $2.11. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $107.38 as of June 30, 2025 at a share price of $2.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio Participates in Nasdaq Amplify Spotlight Series
GlobeNewswire Inc.
9 hours ago
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
GlobeNewswire Inc.
Jun 24, 2025 12:45 PM GMT
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Ge
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management rele